DC-CIK细胞联合化疗治疗局部晚期不可切除或转移性胃腺癌的临床疗效

发布时间：2018-07-13 09:58

【摘要】：目的:探讨自体DC-CIK细胞联合化疗治疗局部晚期不可切除或转移性胃腺癌的临床疗效和安全性。方法:收集2014年11月至2016年7月就诊于中国医学科学院肿瘤医院的32例晚期胃腺癌患者,按照随机对照表法以1∶1分为DC-CIK细胞联合用药组与单药组(每组各16例),两组患者基线资料均衡一致。分别采集PBMC,经实验室体外诱导培养获得DC和CIK细胞。单药组采用替吉奥/奥沙利铂或顺铂化疗方案,联合用药组采用相同化疗方案+DC-CIK细胞治疗。分析比较两组患者治疗前后外周血T淋巴细胞亚群、临床治疗效果、不良反应发生情况和生活质量改善情况。结果:联合用药组患者治疗前后外周血T细胞亚群无明显变化(P0.05),单药组患者化疗后外周血中CD3~+、CD3~+CD4~+、CD3~+CD8~+、CD3~-CD56~+细胞百分比明显低于治疗前(均P0.05)。联合用药组患者疾病控制率、无进展生存期均高于单药组(87.5%vs 50.0%,8.9 vs 4.4个月;均P0.05),两组中位生存期分别为18.0和14.0个月(P0.05)。联合用药组治疗后明显改善了患者因化疗毒副反应或病情本身引起的体力匮乏和失眠,未见治疗相关严重不良反应。结论:DC-CIK细胞联合化疗可明显改善局部晚期不可切除转移性胃腺癌患者免疫状态和生活质量,提高了临床疗效,无明显不良反应。
[Abstract]:Objective: to evaluate the efficacy and safety of autologous DC-CIK cells combined with chemotherapy in the treatment of locally advanced unresectable or metastatic gastric adenocarcinoma. Methods: from November 2014 to July 2016, 32 patients with advanced gastric adenocarcinoma were enrolled in the Cancer Hospital of the Chinese Academy of Medical Sciences. According to the random control table method, 1:1 was divided into DC-CIK cell combination group and single drug group (16 cases in each group). The baseline data of the two groups were balanced and consistent. PBMCs were collected and cultured in vitro to obtain DC and CIK cells. Tigeo / oxaliplatin or cisplatin regimen was used in the single drug group, and DC-CIK cell therapy was used in the combined therapy group. The T lymphocyte subsets of peripheral blood before and after treatment, the clinical effect, the occurrence of adverse reactions and the improvement of quality of life were analyzed and compared between the two groups. Results: there was no significant change of T cell subsets in peripheral blood before and after treatment in combination group (P0.05). The percentage of CD3 ~ + CD3 ~ CD4 ~ + CD3 ~ CD8 ~ + CD3 ~ + -CD56 ~ cells in peripheral blood of single drug group was significantly lower than that before treatment (P0.05). The disease control rate and progression-free survival in combination group were significantly higher than those in single drug group (87.5%vs 50.08.9 vs 4.4 months; P0.05). The median survival time of the two groups was 18.0 and 14.0 months (P0.05). The combined treatment group significantly improved the physical deficiency and insomnia caused by the side effects of chemotherapy or the condition itself, and no serious adverse reactions related to treatment were found. Conclusion the combined chemotherapy with the w DC-CIK cells can significantly improve the immune status and quality of life of the patients with locally advanced unresectable metastatic gastric adenocarcinoma, and improve the clinical efficacy without obvious adverse reactions.
【作者单位】：国家癌症中心中国医学科学院肿瘤医院北京协和医学院肿瘤内科;北京康爱瑞浩生物科技股份有限公司;
【基金】：北京市科技计划项目资助(No.Z14010101101)~~
【分类号】：R735.2

【相似文献】